- E-mailTherese.Sorlie@uib.no
- Phone+47 976 82 544
- Visitor AddressHaukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
- Postal AddressPostboks 78045020 Bergen
Books
- 2005. Genomics in breast cancer - therapeutic implications. 8 pages.
- 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons. 23 pages.
- 2004. Mutation screening of the TP53 gene by Temporal Temperature Gel Electophoresis (TTGE). 9 pages.
Journal articles
- 2019. A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue. Journal of mammary gland biology and neoplasia. 1-13. doi: 10.1007/s10911-018-09423-x
- 2019. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers. Breast Cancer Research. 21: 1-13. doi: 10.1186/s13058-019-1170-8
- 2019. GLI1-induced mammary gland tumours are transplantable and maintain major molecular features. International Journal of Cancer. doi: 10.1002/ijc.32522
- 2019. A Bayesian two-way latent structure model for genomic data integration reveals few pan-genomic cluster subtypes in a breast cancer cohort. Bioinformatics. doi: 10.1093/bioinformatics/btz381
- 2018. Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. Acta Oncologica. 57: 38-43. doi: 10.1080/0284186X.2017.1401735
- 2018. The tankyrase inhibitor G007-LK inhibits small intestine LGR5+ stem cell proliferation without altering tissue morphology. Biological Research (Print). 51. 13 pages. doi: 10.1186/s40659-017-0151-6
- 2017. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discovery. 7: 1098-1115. doi: 10.1158/2159-8290.CD-17-0222
- 2017. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Research. 19. doi: 10.1186/s13058-017-0911-9
- 2016. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. Cell reports. 16: 1166-1179. Published 2016-07-26. doi: 10.1016/j.celrep.2016.06.051
- 2016. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Molecular Medicine. 8: 1052-1064. doi: 10.15252/emmm.201606198
- 2015. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. 15:468. doi: 10.1186/s12885-015-1479-3
- 2015. A conditional transgenic mouse line for targeted expression of the stem cell marker LGR5. Developmental Biology. 404: 35-48. doi: 10.1016/j.ydbio.2015.05.002
- 2015. Glycan-related gene expression signatures in breast cancer subtypes; relation to survival. Molecular Oncology. 9: 861-876. doi: 10.1016/j.molonc.2014.12.013
- 2015. From autonomy to community; new perspectives on tumorigenicity and therapy resistance. Cancer Treatment Reviews. 41: 809-813. doi: 10.1016/j.ctrv.2015.10.004
- 2014. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Research. 16. doi: 10.1186/bcr3597
- 2014. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. British Journal of Surgery. 101: 925-938. doi: 10.1002/bjs.9562
- 2014. Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft. PLOS ONE. 9. doi: 10.1371/journal.pone.0113278
- 2014. Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. Acta Oncologica. 53: 1337-1346. doi: 10.3109/0284186X.2014.925580
- 2014. Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort. Clinical Cancer Research. 20: 5272-5280. doi: 10.1158/1078-0432.CCR-14-0458
- 2014. Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. BMC Cancer. 14. doi: 10.1186/1471-2407-14-211
- 2013. Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Molecular Oncology. 7: 130-142. doi: 10.1016/j.molonc.2012.10.005
- 2013. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Molecular Oncology. 7: 704-718. doi: 10.1016/j.molonc.2013.02.018
- 2013. Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. Virchows Archiv. 463: 775-786. doi: 10.1007/s00428-013-1486-1
- 2013. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer. 13:512. 9 pages. doi: 10.1186/1471-2407-13-512
- 2012. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Annals of Oncology. 23: 2997-3006. doi: 10.1093/annonc/mds586
- 2012. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proceedings of the National Academy of Sciences of the United States of America. 109: 6124-6129. doi: 10.1073/pnas.1203203109
- 2012. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proceedings of the National Academy of Sciences of the United States of America. 109: 2802-2807. doi: 10.1073/pnas.1108781108
- 2011. Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. British Journal of Cancer. 105: 9-12. doi: 10.1038/bjc.2011.203
- 2011. Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue. Molecular Oncology. 5: 564-576. doi: 10.1016/j.molonc.2011.08.004
- 2011. How to personalise treatment in early breast cancer. European Journal of Cancer. 47: S310-S311. doi: 10.1016/S0959-8049(11)70182-4
- 2011. Combining Gene Signatures Improves Prediction of Breast Cancer Survival. PLOS ONE. 6. 15 pages. doi: 10.1371/journal.pone.0017845
- 2010. Transcriptomics meets metabolomics - correlating snapshots of breast cancer metabolism. European Journal of Cancer. 8: 140-140.
- 2010. Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer. 10. 14 pages. doi: 10.1186/1471-2407-10-628
- 2010. On the molecular biology of breast cancer Preface. Molecular Oncology. 4: 171-173. doi: 10.1016/j.molonc.2010.04.007
- 2010. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Molecular Oncology. 4: 357-368. doi: 10.1016/j.molonc.2010.06.007
- 2010. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Research. 12. 10 pages. doi: 10.1186/bcr2466
- 2010. In Silico Ascription of Gene Expression Differences to Tumor and Stromal Cells in a Model to Study Impact on Breast Cancer Outcome. PLOS ONE. 5. doi: 10.1371/journal.pone.0014002
- 2010. Triple-negative breast cancer: Present challenges and new perspectives. Molecular Oncology. 4: 209-229. doi: 10.1016/j.molonc.2010.04.006
- 2010. Glycan gene expression signatures distinguish normal and malignant breast tissue; possible role in diagnosis and progression. European Journal of Cancer. 8: 102-102.
- 2010. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Molecular Oncology. 4: 98-118. doi: 10.1016/j.molonc.2009.12.001
- 2010. Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients. Science Translational Medicine. 2: 38-47. doi: 10.1126/scitranslmed.3000611
- 2010. The importance of gene-centring microarray data. The Lancet Oncology. 11: 719-720.
- 2010. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. European Journal of Cancer. 8: 200-201.
- 2009. Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. Clinical Cancer Research. 15: 3654-3662. doi: 10.1158/1078-0432.CCR-08-3293
- 2009. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Molecular Oncology. 3: 469-482. doi: 10.1016/j.molonc.2009.07.003
- 2009. Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. BMC Medical Genomics. 2. 8 pages. doi: 10.1186/1755-8794-2-26
- 2009. Glycan signatures of breast cancer; possible role in diagnosis and progression of the disease. Annals of Oncology. 20: 49-49.
- 2009. Introducing Molecular Subtyping of Breast Cancer Into the Clinic? Journal of Clinical Oncology. 27: 1153-1154. doi: 10.1200/JCO.2008.20.6276
- 2009. Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution. Molecular Oncology. 3: 214-219. doi: 10.1016/j.molonc.2009.03.001
- 2008. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. Journal of Pathology. 214: 357-367. doi: 10.1002/path.2278
- 2008. Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 123: 577-585. doi: 10.1002/ijc.23541
- 2007. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Molecular Oncology. 1: 160-171. doi: 10.1016/j.molonc.2007.03.004
- 2006. Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 103: 7735-7740.
- 2006. Evaluation of MetriGenix custom 4D (TM) arrays applied for detection of breast cancer subtypes. BMC Cancer. 6. 6 pages. doi: 10.1186/1471-2407-6-59
- 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 5: 2914-2918. doi: 10.1158/1535-7163.MCT-06-0126
- 2005. Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: Clinical implication. Clinical Cancer Research. 11: 878s-883s.
- 2005. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 95: 105-111. doi: 10.1016/j.jsbmb.2005.04.028
- 2005. Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE). Methods in molecular biology. 291: 207-216.
- 2003. Gene expression patterns in ovarian carcinomas. Molecular Biology of the Cell. 14: 4376-4386.
- 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 100: 8418-8423.
- 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proceedings of the National Academy of Sciences of the United States of America. 99: 12963-12968.
- 2001. Microarrays in primary breast cancer -lessons from chemotherapy studies. Endocrine-Related Cancer. 8: 259-263.
- 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 98: 10869-10874.
Book sections
- 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. 5, pages 77-100. In:
- 2004. Oncogenomics: Molecular approaches to cancer. John Wiley & Sons. 382 pages. ISBN: 0-471-22592-4.
More information in national current research information system (CRIStin)